Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05996458
Other study ID # KY20232111-F-1?
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date June 30, 2033

Study information

Verified date July 2023
Source Xijing Hospital
Contact rong zheng
Phone 19829758242
Email zhengrong4956@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer


Description:

group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and SEPTIN9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits. group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled. Group one's control(Spouse or sibling of group one);group two's control(Spouse or sibling of group one): Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc. Finally, 10 years follow-up will be conducted to observe the outcome


Recruitment information / eligibility

Status Recruiting
Enrollment 84000
Est. completion date June 30, 2033
Est. primary completion date November 30, 2032
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 70 Years
Eligibility Inclusion Criteria: - 1. Subjects were 45 to 70 years old when enrolled 2. Willing and able to sign informed consent Exclusion Criteria: - 1. History of any type of malignancy 2. Previous resection of esophagus, stomach or colorectal 3. Received gastrointestinal endoscopy such as colonoscopy and gastroscopy in recent 5 years 4. Have received fecal occult blood test and fecal DNA test in the past 1 year. 5. Contraindications to endoscopy. 6. Warning symptoms of digestive tract tumors, including: 1. Difficulty swallowing, choking or halting feeling when eating recently 2. Recent esophageal foreign body sensation or swallowing pain 3. Recent long-term loss of appetite and appetite 4. Recent and prolonged symptoms of indigestion (including acid reflux, heartburn, abdominal grumbling, burping, nausea or premature satiety, etc.) 5. Recent symptoms of abdominal mass, abdominal pain, vomiting or hematemesis 6. It was medically diagnosed as iron deficiency anemia 7. Recent changes in hematochezia, black stool or stool character and frequency 8. Recent symptoms of perianal discomfort (including soreness, itching, lumps, prolapse or other discomfort) 9. Unexplained weight loss (more than 10% of base body weight) in the past 6 months Step 7 Get pregnant 8. There are other serious comorbiditions that reduce screening benefits (including severe lung disease, advanced kidney disease, advanced liver disease, severe heart failure, etc.)

Study Design


Intervention

Other:
Gastroenteroscopy;Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
Risk factor investigation;
Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
Gastroenteroscopy;Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.

Locations

Country Name City State
China Gaoyao District People's Hospital Zhaoqing Guangzhou

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cancer or precancerous lesions detected Cancer or precancerous lesions detected 10 year
See also
  Status Clinical Trial Phase
Recruiting NCT06002685 - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention N/A
Completed NCT04770259 - Pre-surgical Protocol for Frail Elderly People in Order to Reduce Hospitalization Days (APOPM). N/A
Completed NCT03072472 - BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities N/A